Retina

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

Early detection of incipient geographic atrophy is critical to identify patients at greatest risk of progression and who may benefit most from newly approved complement inhibition therapies.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

The goal of the grant funding from the Choroideremia Research Foundation is to support validation of functional vision assessments for patients with profound blindness.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.

Cleveland, Ohio’s Great Lakes Science Center Community Engagement Coordinator JonDarr Bradshaw details what those in the path of totality should expect, as well as the science center’s initiatives to keep eyes healthy during the event.

Prevent Blindness and the American Optometric Association have released resources and educational information to help the public and eye care providers prepare for the astronomical event on April 8.

The authors suggested genetic mutation may relax the body’s defenses and allow harmful bacteria to reach the eye.

The study focuses on similarities and differences in 11-cis-retinal and mutations in carotenoid cleavage enzymes.

Findings from Mass Eye and Ear’s collaborative study provides new insights regarding gene expression and post-transcriptional gene regulation.

The program, announced prior to ROP Awareness Week, has established an ROP-specific website with free resources for parents and eye care professionals.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.

A task force of eye care providers is asking for feedback on newly-developed guidelines for managing diabetic retinopathy in their patients.

Retinal imaging and genetics data was used to predict future disease risk in a recent study.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

A look back at some of the biggest stories in ophthalmology in 2023.

Catch up on what happened in optometry during the week of December 18-December 22.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

Although the differential diagnosis of pigmented fundus lesions is limited, the distinctions among these lesions are not always clear.

OCU410 is a modifier gene therapy product candidate being developed by Ocugen for dry AMD.

Etiology is crucial to substantive treatment.

Rapid macular thinning often precedes traditional symptoms.

A study surveying retina specialists found surprising results in therapy preference.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

Between 2010 and 2019, this study retrospectively examined and identified all patients diagnosed with syphilitic uveitis who were admitted to inpatient facilities in the United States.